{"id":"NCT00969150","sponsor":"Forest Laboratories","briefTitle":"Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","officialTitle":"A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2010-11","completion":null,"firstPosted":"2009-09-01","resultsPosted":"2013-10-25","lastUpdate":"2013-10-25"},"enrollment":362,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Levomilnacipran ER","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"2","type":"PLACEBO_COMPARATOR"},{"label":"1","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder.","primaryOutcome":{"measure":"Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","timeFrame":"From Baseline to Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-14.2,"sd":0.9},{"arm":"Levomilnacipran ER","deltaMin":-15.7,"sd":0.94}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2492"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":25,"countries":["United States"]},"refs":{"pmids":["27536449","26644957"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":182},"commonTop":["Headache","Nausea","Dry mouth","Insomnia","Upper respiratory tract infection"]}}